Tafinlar/Mekinist
Pre-clinicalRecruiting 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Conditions
BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Trial Timeline
Feb 9, 2024 → Dec 31, 2031
NCT ID
NCT06262919About Tafinlar/Mekinist
Tafinlar/Mekinist is a pre-clinical stage product being developed by Novartis for BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06262919. Target conditions include BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06262919 | Pre-clinical | Recruiting |
Competing Products
13 competing products in BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PLX3397 + vemurafenib | Daiichi Sankyo | Phase 1 | 33 |
| TMZ + E7016 | Eisai | Phase 2 | 52 |
| Encorafenib + Binimetinib + Cetuximab + Irinotecan + Folinic Acid + 5-Fluorouracil | Ono Pharmaceutical | Phase 3 | 77 |
| encorafenib + Binimetinib + Cetuximab | Ono Pharmaceutical | Phase 2 | 52 |
| Encorafenib + Cetuximab + FOLFIRI | Merck | Phase 2 | 52 |
| BKM120 Combined with Vemurafenib (PLX4032) | Novartis | Phase 1/2 | 41 |
| Dabrafenib + LTT462 + Trametinib + LXH254 + TNO155 + Spartalizumab + Tislelizumab | Novartis | Phase 1 | 33 |
| Cobimetinib + Atezolizumab + Pembrolizumab | Roche | Phase 3 | 77 |
| LGX818 + MEK162 + LEE011 | Pfizer | Phase 1/2 | 40 |
| MEK162 | Pfizer | Phase 2 | 51 |
| Encorafenib + Binimetinib + cemiplimab+fianlimab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Plixorafenib + Cobicistat 150 MG [Tybost] | Brain Biotech | Phase 1 | 25 |
| Dabrafenib + Trametinib + Hydroxychloroquine | Brain Biotech | Phase 1/2 | 33 |